# US 11,432,578 B2 · Mixture of HMOs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,432,578 B2
- Document ID: US11432578B2
- Status: Granted
- Kind: B2
- Application number: 16/062,598
- Filed: 2016-12-15
- Published: 2018-12-27
- Granted: 2022-09-06
- Earliest claimed: 2015-12-15
- Assignees: Glycom A/S
- Applicants: Glycom A/S
- Inventors: Bruce McConnell; Louise Kristine Vignæs
- Web page: https://patentgrep.com/patent/US11432578B2

## CPC

- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/19: Dairy proteins
- A23L 33/195: Proteins from microorganisms
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.

## Claims

### Claim 1

A method of treating a viral infection in a non-infant human, comprising: administering to the non-infant human a synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2′-O-fucosyllactose (2′-FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL), either 3-fucosyllactose (3-FL) or difucosyllactose (DFL), and optionally lactose.

### Claim 2 (depends on 1)

The method of claim 1, wherein the synthetic mixture consists essentially of LNnT, LNT, 2′-FL, 3′-SL, 6′-SL, DFL and, optionally, lactose.

### Claim 3 (depends on 2)

The method of claim 2, wherein the synthetic mixture consists essentially of
i. about 55 wt % to about 75 wt % of 2′-FL;
ii. about 2 wt % to about 10 wt % of LNnT;
iii. about 10 wt % to about 20 wt % of LNT;
iv. about 1 wt % to about 15 wt % of DFL;
v. about 1 wt % to about 10 wt % of 3′-SL; and
vi. about 1 wt % to about 15 wt % of 6′-SL.

### Claim 4 (depends on 1)

The method of claim 1, wherein the synthetic mixture consists essentially of
i. about 55 wt % to about 75 wt % of 2′-FL;
ii. about 2 wt % to about 10 wt % of LNnT;
iii. about 10 wt % to about 20 wt % of LNT;
iv. about 1 wt % to about 15 wt % of 3-FL;
v. about 1 wt % to about 10 wt % of 3′-SL; and
vi. about 1 wt % to about 15 wt % of 6′-SL.

### Claim 5 (depends on 4)

The method of claim 4, wherein the synthetic mixture consists essentially of
i. about 60 wt % to about 70 wt % of 2′-FL;
ii. about 3 wt % to about 7 wt % of LNnT;
iii. about 12 wt % to about 18 wt % of LNT;
iv. about 2 wt % to about 10 wt % of 3-FL;
v. about 2 wt % to about 8 wt % of 3′-SL; and
vi. about 5 wt % to about 15 wt % of 6′-SL.

### Claim 6 (depends on 1)

The method of claim 1, wherein the synthetic mixture is a component of a nutritional or a pharmaceutical composition.

### Claim 7 (depends on 1)

The method of claim 1, wherein the viral infection is influenza.